NO332275B1 - Fast underlag for immunoanalyse, fremgangsmate for fremstilling derav, fremgangsmater for pavising av hepatitt C virus (HCV) infeksjon i en prove samt immunodiagnostisk testkit. - Google Patents

Fast underlag for immunoanalyse, fremgangsmate for fremstilling derav, fremgangsmater for pavising av hepatitt C virus (HCV) infeksjon i en prove samt immunodiagnostisk testkit. Download PDF

Info

Publication number: NO332275B1
Authority: NO; Norway
Prior art keywords: hcv; antibody; core; epitope; antigen
Prior art date: 2000-06-15

Application number

NO20025878A

Other languages

English (en)

Norwegian (no)

Other versions

NO20025878D0 (no

NO20025878L (no

Inventor

David Y Chien

Phillip Arcangel

Laura Tandeske

Carlos George-Nasciemento

Doris Coit

Angelica Medina-Selby

Original Assignee

Novartis Vaccines & Diagnostic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-15

Filing date

2002-12-06

Publication date

2012-08-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27395684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO332275(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-12-06 Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic

2002-12-06 Publication of NO20025878D0 publication Critical patent/NO20025878D0/no

2003-02-12 Publication of NO20025878L publication Critical patent/NO20025878L/no

2012-08-13 Publication of NO332275B1 publication Critical patent/NO332275B1/no

Links

239000007787 solid Substances 0.000 title claims abstract description 111
238000003018 immunoassay Methods 0.000 title claims abstract description 39
241000711549 Hepacivirus C Species 0.000 title claims description 273
238000000034 method Methods 0.000 title claims description 107
239000000758 substrate Substances 0.000 title claims description 65
208000015181 infectious disease Diseases 0.000 title claims description 38
238000012360 testing method Methods 0.000 title claims description 15
238000002360 preparation method Methods 0.000 title description 12
239000000427 antigen Substances 0.000 claims abstract description 205
102000036639 antigens Human genes 0.000 claims abstract description 205
108091007433 antigens Proteins 0.000 claims abstract description 205
108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 claims abstract description 43
108010076039 Polyproteins Proteins 0.000 claims description 85
150000001413 amino acids Chemical class 0.000 claims description 83
239000012472 biological sample Substances 0.000 claims description 76
125000003275 alpha amino acid group Chemical group 0.000 claims description 73
230000004927 fusion Effects 0.000 claims description 32
238000001514 detection method Methods 0.000 claims description 25
230000027455 binding Effects 0.000 claims description 23
230000003460 anti-nuclear Effects 0.000 claims description 19
238000006467 substitution reaction Methods 0.000 claims description 17
210000004899 c-terminal region Anatomy 0.000 claims description 13
230000000536 complexating effect Effects 0.000 claims description 13
238000012217 deletion Methods 0.000 claims description 13
230000037430 deletion Effects 0.000 claims description 13
210000004897 n-terminal region Anatomy 0.000 claims description 10
102000019197 Superoxide Dismutase Human genes 0.000 claims description 6
108010012715 Superoxide dismutase Proteins 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
101710132601 Capsid protein Proteins 0.000 claims description 2
101100017043 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HIR3 gene Proteins 0.000 claims 1
238000003556 assay Methods 0.000 abstract description 48
239000011159 matrix material Substances 0.000 abstract description 5
101710144111 Non-structural protein 3 Proteins 0.000 description 136
235000001014 amino acid Nutrition 0.000 description 83
229940024606 amino acid Drugs 0.000 description 75
108090000765 processed proteins & peptides Proteins 0.000 description 64
102000004196 processed proteins & peptides Human genes 0.000 description 59
108090000623 proteins and genes Proteins 0.000 description 55
229920001184 polypeptide Polymers 0.000 description 53
102000004169 proteins and genes Human genes 0.000 description 42
235000018102 proteins Nutrition 0.000 description 41
210000004027 cell Anatomy 0.000 description 38
239000012634 fragment Substances 0.000 description 37
239000000523 sample Substances 0.000 description 28
108091026890 Coding region Proteins 0.000 description 25
230000014509 gene expression Effects 0.000 description 25
238000004458 analytical method Methods 0.000 description 23
230000000694 effects Effects 0.000 description 20
241000276498 Pollachius virens Species 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
108060004795 Methyltransferase Proteins 0.000 description 14
239000013598 vector Substances 0.000 description 14
230000003612 virological effect Effects 0.000 description 14
230000000890 antigenic effect Effects 0.000 description 13
108010001336 Horseradish Peroxidase Proteins 0.000 description 12
239000000203 mixture Substances 0.000 description 12
108020004414 DNA Proteins 0.000 description 11
238000003776 cleavage reaction Methods 0.000 description 11
239000008188 pellet Substances 0.000 description 11
230000007017 scission Effects 0.000 description 11
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
240000004808 Saccharomyces cerevisiae Species 0.000 description 10
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
108091033319 polynucleotide Proteins 0.000 description 10
102000040430 polynucleotide Human genes 0.000 description 10
239000002157 polynucleotide Substances 0.000 description 10
239000000047 product Substances 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
239000011324 bead Substances 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
230000001105 regulatory effect Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
108091005804 Peptidases Proteins 0.000 description 8
239000004365 Protease Substances 0.000 description 8
241000700605 Viruses Species 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
102000037865 fusion proteins Human genes 0.000 description 8
108020001507 fusion proteins Proteins 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 7
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 7
239000013604 expression vector Substances 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
108091035707 Consensus sequence Proteins 0.000 description 6
238000007792 addition Methods 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
229910052921 ammonium sulfate Inorganic materials 0.000 description 6
235000011130 ammonium sulphate Nutrition 0.000 description 6
-1 aromatic amino acids Chemical class 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
230000001900 immune effect Effects 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
235000019419 proteases Nutrition 0.000 description 6
230000010076 replication Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000007790 solid phase Substances 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
241000238631 Hexapoda Species 0.000 description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
101800001838 Serine protease/helicase NS3 Proteins 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
238000010367 cloning Methods 0.000 description 5
230000003053 immunization Effects 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
239000003446 ligand Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
230000000717 retained effect Effects 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
108020004705 Codon Proteins 0.000 description 4
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
102000012479 Serine Proteases Human genes 0.000 description 4
108010022999 Serine Proteases Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
239000006167 equilibration buffer Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000002741 site-directed mutagenesis Methods 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000009466 transformation Effects 0.000 description 4
241000701447 unidentified baculovirus Species 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000010836 blood and blood product Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000004590 computer program Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
210000003292 kidney cell Anatomy 0.000 description 3
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
108010052968 leupeptin Proteins 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
238000013507 mapping Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
238000006384 oligomerization reaction Methods 0.000 description 3
108010091212 pepstatin Proteins 0.000 description 3
229950000964 pepstatin Drugs 0.000 description 3
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000005030 transcription termination Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
230000014616 translation Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 2
101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
206010019791 Hepatitis post transfusion Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
241001625930 Luria Species 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
241001529936 Murinae Species 0.000 description 2
102000019040 Nuclear Antigens Human genes 0.000 description 2
108010051791 Nuclear Antigens Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
108090000944 RNA Helicases Proteins 0.000 description 2
102000004409 RNA Helicases Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
101710172711 Structural protein Proteins 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
230000003321 amplification Effects 0.000 description 2
229940009098 aspartate Drugs 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000008859 change Effects 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
239000011536 extraction buffer Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000037433 frameshift Effects 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
239000012510 hollow fiber Substances 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000002169 hydrotherapy Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
230000035800 maturation Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
241000894007 species Species 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000001890 transfection Methods 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
239000004474 valine Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
101150031523 4a gene Proteins 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
241000256118 Aedes aegypti Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000255789 Bombyx mori Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000222128 Candida maltosa Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
QLAKAJLYYGOZQL-UHFFFAOYSA-N Carboxyphosphamide Chemical compound ClCCN(CCCl)P(=O)(N)OCCC(O)=O QLAKAJLYYGOZQL-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241001227713 Chiron Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
238000011537 Coomassie blue staining Methods 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
244000285963 Kluyveromyces fragilis Species 0.000 description 1
235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
241001138401 Kluyveromyces lactis Species 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101800001020 Non-structural protein 4A Proteins 0.000 description 1
101150038760 Ns3 gene Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000320412 Ogataea angusta Species 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
239000004642 Polyimide Substances 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
241000255993 Trichoplusia ni Species 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
241000235015 Yarrowia lipolytica Species 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
238000005844 autocatalytic reaction Methods 0.000 description 1
RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000004695 complexes Chemical class 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000012258 culturing Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
230000006334 disulfide bridging Effects 0.000 description 1
NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
125000003700 epoxy group Chemical group 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
238000012203 high throughput assay Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229940065638 intron a Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000008267 milk Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229940079938 nitrocellulose Drugs 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000013081 phylogenetic analysis Methods 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000553 poly(phenylenevinylene) Polymers 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000015 polydiacetylene Polymers 0.000 description 1
229920000647 polyepoxide Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001721 polyimide Polymers 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
229920000128 polypyrrole Polymers 0.000 description 1
229920000123 polythiophene Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000005373 porous glass Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000002821 scintillation proximity assay Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000008279 sol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
238000011282 treatment Methods 0.000 description 1
ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000012795 verification Methods 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Investigating Or Analysing Biological Materials (AREA)
Plural Heterocyclic Compounds (AREA)

NO20025878A 2000-06-15 2002-12-06 Fast underlag for immunoanalyse, fremgangsmate for fremstilling derav, fremgangsmater for pavising av hepatitt C virus (HCV) infeksjon i en prove samt immunodiagnostisk testkit. NO332275B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US21208200P	2000-06-15	2000-06-15
US28081101P	2001-04-02	2001-04-02
US28086701P	2001-04-02	2001-04-02
PCT/US2001/019369 WO2001096875A2 (en)	2000-06-15	2001-06-14	Hcv antigen/antibody combination assay

Publications (3)

Publication Number	Publication Date
NO20025878D0 NO20025878D0 (no)	2002-12-06
NO20025878L NO20025878L (no)	2003-02-12
NO332275B1 true NO332275B1 (no)	2012-08-13

Family

ID=27395684

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20025878A NO332275B1 (no)	2000-06-15	2002-12-06	Fast underlag for immunoanalyse, fremgangsmate for fremstilling derav, fremgangsmater for pavising av hepatitt C virus (HCV) infeksjon i en prove samt immunodiagnostisk testkit.

Country Status (22)

Country	Link
US (5)	US6632601B2 (de)
EP (2)	EP1350105B1 (de)
JP (3)	JP4834279B2 (de)
CN (3)	CN1214244C (de)
AT (2)	ATE368221T1 (de)
AU (2)	AU2001272948A1 (de)
BG (1)	BG66205B1 (de)
BR (2)	BRPI0111731C1 (de)
CA (2)	CA2412035C (de)
CY (2)	CY1107537T1 (de)
CZ (1)	CZ304185B6 (de)
DE (2)	DE60125240T3 (de)
DK (2)	DK1350105T3 (de)
ES (2)	ES2277932T5 (de)
HU (1)	HU228873B1 (de)
MX (2)	MXPA02012424A (de)
NO (1)	NO332275B1 (de)
PL (1)	PL213363B1 (de)
PT (2)	PT1354204E (de)
SI (1)	SI1354204T2 (de)
SK (1)	SK287694B6 (de)
WO (2)	WO2001096870A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69433160T2 (de) *	1993-05-12	2004-07-08	Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville	Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
US7491808B2 (en) *	2000-06-15	2009-02-17	Novartis Vaccines And Diagnostics, Inc.	HCV non-structural protein mutants and uses thereof
SK287694B6 (sk) *	2000-06-15	2011-06-06	Novartis Vaccines & Diagnostics, Inc.	Pevný nosič imunoeseje a spôsob jeho prípravy, spôsob detekcie infekcie HIV a súprava na imunodiagnostickú skúšku
US6858590B2 (en)	2000-08-17	2005-02-22	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
AU2001292151B2 (en) *	2000-08-17	2006-05-04	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en)	2000-08-17	2006-04-04	Tripep Ab	Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en)	2000-08-29	2004-01-20	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
DE10106295C1 (de) *	2001-02-02	2002-08-22	Gaifar German American Inst Fo	Protein mit mehreren Antigen-Epitop-Sequenzen, welches immobilisiert ist
AU785380B2 (en) *	2001-03-28	2007-03-15	Ortho-Clinical Diagnostics, Inc.	A hepatitis C antigen - antibody combination assay for the early detection of HCV infection
US7101683B2 (en) *	2001-06-26	2006-09-05	Abbott Laboratories	Methods for the simultaneous detection of HCV antigens and HCV antibodies
JP4353793B2 (ja)	2001-06-26	2009-10-28	アボット・ラボラトリーズ	Ｈｃｖ抗原とｈｃｖ抗体との同時検出のための方法
US7049060B2 (en) *	2001-11-05	2006-05-23	Ortho-Clinical Diagnostics, Inc.	HCV anti-core monoclonal antibodies
US7332269B2 (en) *	2001-11-11	2008-02-19	Ortho-Clinical Diagnostics, Inc.	HCV core protein sequences
FR2839555B1 (fr)	2002-05-10	2007-07-27	Bio Rad Pasteur	Procede de detection simultanee d'un antigene et d'un anticorps d'un microorganisme infectieux
US7166426B2 (en) *	2002-09-09	2007-01-23	Novartis Vaccines And Diagnostics, Inc.	HCV assay
US20040152070A1 (en) *	2003-02-04	2004-08-05	Shah Dinesh O.	Method of detection of HCV antibodies in combination assay or sole antibody assay
EP1668369B1 (de)	2003-08-20	2016-01-06	ProMIS Neurosciences Inc.	Epitopschutztest und verfahren zum nachweis von proteinkonformationen
ATE542140T1 (de) *	2004-08-27	2012-02-15	Novartis Vaccines & Diagnostic	Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür
WO2006081701A1 (fr) *	2005-02-02	2006-08-10	Peng Cui	Kit de detection de l'anticorps du vhc et procede de preparation de celui-ci
AU2006335256B2 (en)	2005-11-22	2012-10-18	Novartis Vaccines And Diagnostics, Inc.	Norovirus and sapovirus antigens
US7887803B2 (en)	2005-12-02	2011-02-15	Amorfix Life Sciences	Methods and compositions to treat misfolded-SOD1 mediated diseases
US7794692B2 (en) *	2005-12-02	2010-09-14	Amorfix Life Sciences Ltd.	Methods and compositions for detecting amyotrophic lateral sclerosis
DK2514823T3 (en)	2006-03-03	2018-07-23	Promis Neurosciences Inc	Methods and compositions for treating and detecting failed SOD1-mediated diseases
CN1908666B (zh) *	2006-08-14	2010-05-12	武汉大学	一种检测乙肝核心抗体的双夹心法酶联免疫诊断试剂盒及应用
WO2009022236A2 (en)	2007-08-16	2009-02-19	Tripep Ab	Immunogen platform
WO2010112733A1 (fr) *	2009-03-30	2010-10-07	bioMérieux	Support solide de détection du vhc
US20100297607A1 (en) *	2009-05-20	2010-11-25	Jian Zheng	Reagents For HCV Antigen-Antibody Combination Assays
JP2013529894A (ja)	2010-04-07	2013-07-25	ノバルティスアーゲー	パルボウイルスｂ１９のウイルス様粒子を生成するための方法
CN102947703A (zh) *	2010-06-17	2013-02-27	皇家飞利浦电子股份有限公司	多表位测定
CA2804501C (en)	2010-07-06	2021-01-26	Novartis Ag	Noro virus derived immunogenic compositions and methods
WO2012006500A2 (en) *	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
BR112013017961A2 (pt) *	2011-01-13	2017-07-25	Ortho Clinical Diagnostics Inc	antígeno tripleto para treponema pallidum
FR2984328B1 (fr)	2011-12-20	2016-12-30	Bio-Rad Innovations	Procede de detection d'une infection par le virus de l'hepatite c
CN105378099B (zh)	2013-03-14	2021-05-11	雅培制药有限公司	Hcv核心脂质结合结构域单克隆抗体
EP2970947A4 (de)	2013-03-14	2016-10-12	Abbott Lab	Rekombinante hcv-ns3-antigene und mutanten für den verbesserten nachweis von antikörpern
JP6505076B2 (ja)	2013-03-14	2019-04-24	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
CN103630690B (zh) *	2013-12-17	2014-08-20	朱之炜	丙型肝炎病毒抗原抗体联合检测试剂盒及其检测方法
EP3274478B1 (de)	2015-03-27	2020-09-23	Ortho-Clinical Diagnostics, Inc.	Hcv-ns4a/modifizierte ns3-polypeptide und verwendungen davon
WO2016172121A1 (en) *	2015-04-20	2016-10-27	Qoolabs, Inc.	Camelid single-domain hcv antibodies and methods of use
EP3688185B1 (de) *	2017-09-27	2023-01-18	Bio-Rad Laboratories, Inc.	Test für digitale affinitätsverknüpfung
CN110261616B (zh) *	2019-04-30	2021-07-20	广东菲鹏生物有限公司	一种丙型肝炎病毒检测试剂盒
CN115057943B (zh) *	2022-06-22	2025-03-14	杭州水芭莎生物医药科技有限公司	一种抗菌肽融合蛋白及其制备方法和应用
CN115838420B (zh) *	2022-10-31	2023-05-05	北京科跃中楷生物技术有限公司	一种可溶性hcv重组蛋白的制备方法及其制备的抗体检测试剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2212511B (en) *	1987-11-18	1992-01-22	Chiron Corp	Hepatitis c virus
US5350671A (en)	1987-11-18	1994-09-27	Chiron Corporation	HCV immunoassays employing C domain antigens
BR8807310A (pt) *	1987-11-18	1990-03-13	Chiron Corp	Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
US6171782B1 (en)	1987-11-18	2001-01-09	Chiron Corporation	Antibody compositions to HCV and uses thereof
US5683864A (en) *	1987-11-18	1997-11-04	Chiron Corporation	Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
JP2730153B2 (ja)	1989-03-16	1998-03-25	日本合成ゴム株式会社	熱可塑性樹脂組成物およびその製造方法
HU225068B1 (en)	1989-03-17	2006-05-29	Chiron Corp	Process for producing diagnostics and vaccine of nanbh
JP2656996B2 (ja) *	1989-05-18	1997-09-24	カイロンコーポレイション	Ｎａｎｂｖの診断用薬
US6194140B1 (en) *	1990-04-04	2001-02-27	Chiron Corporation	HCV NS3 protein fragments having helicase activity and improved solubility
US5712087A (en)	1990-04-04	1998-01-27	Chiron Corporation	Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
WO1991015771A1 (en) *	1990-04-04	1991-10-17	Chiron Corporation	Combinations of hepatitis c virus (hcv) antigens for use in immunoassays for anti-hcv antibodies
CA2049679C (en) *	1990-08-24	2005-06-21	Sushil G. Devare	Hepatitis c assay utilizing recombinant antigens
PT97247B (pt) *	1991-04-03	1997-10-31	Chiron Corp	Processo de preparacao de combinacoes de antigenios do virus da hepapite c (hcv) para uso em imunoensaios para anticorpos anti-hcv
KR0185426B1 (ko)	1991-06-24	1999-04-01	로버트 피. 블랙버언	씨형 간염 바이러스 폴리펩티드
UA39944C2 (uk)	1992-07-07	2001-07-16	Чірон Корпорейшн	Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
ATE551423T1 (de) *	1993-04-27	2012-04-15	Innogenetics Nv	Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
US6001604A (en) *	1993-12-29	1999-12-14	Bio-Technology General Corp.	Refolding of proinsulins without addition of reducing agents
JP3217600B2 (ja)	1994-07-12	2001-10-09	株式会社先端生命科学研究所	非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ
DE4428705A1 (de) *	1994-08-12	1996-02-15	Boehringer Mannheim Gmbh	Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
US5843752A (en)	1995-05-12	1998-12-01	Schering Corporation	Soluble active hepatitis C virus protease
US5990276A (en)	1996-05-10	1999-11-23	Schering Corporation	Synthetic inhibitors of hepatitis C virus NS3 protease
US6514731B1 (en) *	1996-05-24	2003-02-04	Chiron Corporation	Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
JP3945822B2 (ja)	1996-05-24	2007-07-18	カイロンコーポレイション	複数エピトープ融合タンパク質
EP0870830A3 (de) *	1997-02-10	2004-02-25	Advanced Life Science Institute, Inc.	Chimäres Hepatitis C-Virusantigen
PT1021719E (pt) *	1997-09-22	2007-03-30	Novartis Vaccines & Diagnostic	Método para detecção de anticorpos numa amostra
JP3514729B2 (ja) *	1998-07-30	2004-03-31	株式会社先端生命科学研究所	Ｃ型肝炎ウイルスの測定方法
SK287694B6 (sk) *	2000-06-15	2011-06-06	Novartis Vaccines & Diagnostics, Inc.	Pevný nosič imunoeseje a spôsob jeho prípravy, spôsob detekcie infekcie HIV a súprava na imunodiagnostickú skúšku

2001
- 2001-06-14 SK SK1777-2002A patent/SK287694B6/sk not_active IP Right Cessation
- 2001-06-14 PL PL365599A patent/PL213363B1/pl not_active IP Right Cessation
- 2001-06-14 CA CA2412035A patent/CA2412035C/en not_active Expired - Lifetime
- 2001-06-14 WO PCT/US2001/019156 patent/WO2001096870A2/en not_active Ceased
- 2001-06-14 SI SI200130682T patent/SI1354204T2/sl unknown
- 2001-06-14 AU AU2001272948A patent/AU2001272948A1/en not_active Abandoned
- 2001-06-14 DE DE60125240T patent/DE60125240T3/de not_active Expired - Lifetime
- 2001-06-14 WO PCT/US2001/019369 patent/WO2001096875A2/en not_active Ceased
- 2001-06-14 EP EP01952156A patent/EP1350105B1/de not_active Expired - Lifetime
- 2001-06-14 US US09/881,654 patent/US6632601B2/en not_active Expired - Lifetime
- 2001-06-14 MX MXPA02012424A patent/MXPA02012424A/es active IP Right Grant
- 2001-06-14 AT AT01952156T patent/ATE368221T1/de active
- 2001-06-14 JP JP2002510953A patent/JP4834279B2/ja not_active Expired - Lifetime
- 2001-06-14 ES ES01952160T patent/ES2277932T5/es not_active Expired - Lifetime
- 2001-06-14 DE DE60129598T patent/DE60129598T2/de not_active Expired - Lifetime
- 2001-06-14 MX MXPA02012401A patent/MXPA02012401A/es active IP Right Grant
- 2001-06-14 ES ES01952156T patent/ES2288969T3/es not_active Expired - Lifetime
- 2001-06-14 HU HU0500444A patent/HU228873B1/hu unknown
- 2001-06-14 CZ CZ20024058A patent/CZ304185B6/cs not_active IP Right Cessation
- 2001-06-14 CN CNB018112463A patent/CN1214244C/zh not_active Expired - Lifetime
- 2001-06-14 BR BRPI0111731A patent/BRPI0111731C1/pt not_active IP Right Cessation
- 2001-06-14 EP EP01952160A patent/EP1354204B2/de not_active Expired - Lifetime
- 2001-06-14 AT AT01952160T patent/ATE348337T1/de active
- 2001-06-14 PT PT01952160T patent/PT1354204E/pt unknown
- 2001-06-14 CN CNB2004100116606A patent/CN100463922C/zh not_active Expired - Lifetime
- 2001-06-14 PT PT01952156T patent/PT1350105E/pt unknown
- 2001-06-14 BR BRPI0111682A patent/BRPI0111682B8/pt not_active IP Right Cessation
- 2001-06-14 JP JP2002510948A patent/JP4837229B2/ja not_active Expired - Lifetime
- 2001-06-14 CA CA2413003A patent/CA2413003C/en not_active Expired - Lifetime
- 2001-06-14 US US09/881,239 patent/US6630298B2/en not_active Expired - Lifetime
- 2001-06-14 CN CNB018112439A patent/CN1256591C/zh not_active Expired - Lifetime
- 2001-06-14 DK DK01952156T patent/DK1350105T3/da active
- 2001-06-14 AU AU2001272945A patent/AU2001272945A1/en not_active Abandoned
- 2001-06-14 DK DK01952160.8T patent/DK1354204T4/da active
2002
- 2002-12-06 NO NO20025878A patent/NO332275B1/no not_active IP Right Cessation
2003
- 2003-01-07 BG BG107441A patent/BG66205B1/bg unknown
- 2003-08-08 US US10/637,323 patent/US6797809B2/en not_active Expired - Lifetime
- 2003-08-19 US US10/643,853 patent/US7319144B2/en not_active Expired - Lifetime
2004
- 2004-07-26 US US10/899,715 patent/US7241879B2/en not_active Expired - Lifetime
2007
- 2007-03-07 CY CY20071100319T patent/CY1107537T1/el unknown
- 2007-08-20 CY CY20071101092T patent/CY1106820T1/el unknown
2011
- 2011-03-28 JP JP2011071150A patent/JP2011125350A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
BR0111682A (pt)	2004-01-06
ES2277932T3 (es)	2007-08-01
CY1107537T1 (el)	2013-03-13
AU2001272945A1 (en)	2001-12-24
JP2004506878A (ja)	2004-03-04
HK1061861A1 (en)	2004-10-08
CA2412035C (en)	2012-04-10
CZ304185B6 (cs)	2013-12-11
WO2001096875A3 (en)	2003-08-28
MXPA02012424A (es)	2003-04-25
NO20025878D0 (no)	2002-12-06
AU2001272948A1 (en)	2001-12-24
US6797809B2 (en)	2004-09-28
SK287694B6 (sk)	2011-06-06
CN1660913A (zh)	2005-08-31
HK1079796A1 (en)	2006-04-13
US20040063092A1 (en)	2004-04-01
EP1354204B1 (de)	2006-12-13
CN1214244C (zh)	2005-08-10
WO2001096870A2 (en)	2001-12-20
EP1350105A2 (de)	2003-10-08
DE60129598T2 (de)	2008-04-17
CN100463922C (zh)	2009-02-25
WO2001096875A9 (en)	2002-08-15
US20020192639A1 (en)	2002-12-19
DE60129598D1 (de)	2007-09-06
US7241879B2 (en)	2007-07-10
US7319144B2 (en)	2008-01-15
CZ20024058A3 (cs)	2003-09-17
BRPI0111731C1 (pt)	2021-07-27
ES2277932T5 (es)	2010-06-28
BRPI0111731B8 (pt)	2016-08-23
CA2412035A1 (en)	2001-12-20
CN1256591C (zh)	2006-05-17
WO2001096875A2 (en)	2001-12-20
BG107441A (bg)	2004-01-30
BRPI0111682B1 (pt)	2017-09-19
PL365599A1 (en)	2005-01-10
ATE368221T1 (de)	2007-08-15
CA2413003A1 (en)	2001-12-20
US20040096822A1 (en)	2004-05-20
PT1354204E (pt)	2007-03-30
US20020146685A1 (en)	2002-10-10
SI1354204T2 (sl)	2010-09-30
US6632601B2 (en)	2003-10-14
BRPI0111731B1 (pt)	2016-07-05
HUP0500444A3 (en)	2010-03-29
BR0111731A (pt)	2004-02-10
MXPA02012401A (es)	2003-04-25
NO20025878L (no)	2003-02-12
DE60125240T2 (de)	2007-07-12
CA2413003C (en)	2013-08-13
PT1350105E (pt)	2007-08-13
BG66205B1 (bg)	2012-01-31
JP2011125350A (ja)	2011-06-30
DE60125240T3 (de)	2010-10-28
DK1354204T4 (da)	2010-06-14
BRPI0111682B8 (pt)	2021-07-27
DK1350105T3 (da)	2007-11-12
WO2001096870A3 (en)	2003-07-31
DE60125240D1 (de)	2007-01-25
JP2004510133A (ja)	2004-04-02
SK17772002A3 (sk)	2003-10-07
US20040265801A1 (en)	2004-12-30
CN1489692A (zh)	2004-04-14
EP1350105B1 (de)	2007-07-25
EP1354204B2 (de)	2010-04-21
CY1106820T1 (el)	2012-05-23
HU228873B1 (hu)	2013-06-28
JP4834279B2 (ja)	2011-12-14
CN1466682A (zh)	2004-01-07
DK1354204T3 (da)	2007-04-10
US6630298B2 (en)	2003-10-07
PL213363B1 (pl)	2013-02-28
EP1354204A2 (de)	2003-10-22
JP4837229B2 (ja)	2011-12-14
ATE348337T1 (de)	2007-01-15
ES2288969T3 (es)	2008-02-01
HUP0500444A2 (hu)	2005-08-29
SI1354204T1 (sl)	2007-04-30

Legal Events

Date	Code	Title	Description
2015-05-18	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: GRIFOLS WORDWIDE OPERATIONS LIMITED, IE
2015-05-18	CREP	Change of representative	Representative=s name: BRYN AARFLOT AS, POSTBOKS 449 SENTRUM, 0104 OSLO
2015-12-14	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: GRIFOLS WORLDWIDE OPERATIONS LIMITED, IE
2021-07-12	MK1K	Patent expired

Publication	Publication Date	Title
EP1354204B2 (de)	2010-04-21	Hcv-antigen/antikörper-kombinations-assay
US7166426B2 (en)	2007-01-23	HCV assay
US10753939B2 (en)	2020-08-25	HCV NS4a/modified NS3 polypeptides and uses thereof
EP1799868B1 (de)	2012-01-18	Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür
RU2274863C2 (ru)	2006-04-20	Определение комплекса hcv-антиген/антитело
EP1829891B1 (de)	2012-12-26	Immuntests für Anti-HCV-Antikörper